WHIPPANY, NJ–(BUSINESS WIRE)–Bayer announced today that Sebastian Guth, president of Bayer Pharmaceuticals, Americas and member of the global Pharmaceutical Executive Committee, has been named to the PharmaVoice 100, an annual list of the most inspiring leaders in the life sciences industry, representing innovators; circuit breakers; and champions of diversity, equity and inclusion.
A 20-year veteran of the pharmaceutical industry, Guth oversees operations for Bayer Pharmaceuticals in the United States, the company’s largest market, as well as Canada and Latin America. He is consistently recognized as a visionary and inspirational leader committed to bringing about new healthcare solutions and providing equal access to healthcare for all people.
“I am incredibly proud to lead our employees across America in advancing the meaningful work we do every day,” Guth said. “Each of us is deeply committed to helping all people live healthier lives. It is an honor to be recognized by my peers as a PharmaVoice 100 recipient.”
Since assuming his role nearly four years ago, Guth and his team have accelerated the growth of the North American business, reaching $4.86 billion in pharmaceutical sales last year. He led a cultural transformation of the business that increased employee engagement by 18 percent during his first two years as president; and fostered diversity within its leadership team, moving from 15 percent to a 50 percent female-led team today.
Guth serves as a member of the Board of Trustees for Children’s Aid, a New York-based organization that works to help children in poverty succeed. He has championed many important initiatives, including expanding Bayer’s partnership with Direct Relief, a nonprofit humanitarian organization to fund health clinics across the United States to provide education and access to reproductive health services to underserved women. Guth has also supported Bayer’s leadership position in several population health organizations on behalf of the company, including the Population Health Alliance, the Pharmacy Quality Alliance and the National Alliance of Healthcare Buyer Coalitions.
“Sebastian is a transformational leader who believes that culture is the glue that holds everyone together and is what turns a good organization into a great organization,” said Simon Rosof, vice president of oncology sales and marketing North America , who nominated Guth and has worked with him in many roles. “When he sees an opportunity to advance patient care, he rallies the organization around him to act with speed, determination and total commitment to the people we serve.”
On September 15, Guth will join the PharmaVoice 100 2022 celebration as a panelist during its virtual event, The next era of leadership, from 10-11 a.m. ET. Register for the event at PharmaVoice 100 Celebration: The Next Era of Leadership (industrydive.com).
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges posed by a growing and aging global population. Bayer is committed to fostering sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality worldwide. In fiscal year 2021, the Group employed around 100,000 people and had sales of €44.1 billion. R&D expenditure before special items amounted to EUR 5.3 billion. For more information, go to www.bayer.com.
Follow Guth on LinkedIn: https://www.linkedin.com/in/sebastian-guth-4a83175a/
Find more information at https://pharma.bayer.com/
Follow Bayer on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma
Forward-looking statements
This release may contain forward-looking statements based on current assumptions and projections made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given herein. These factors include those discussed in Bayer’s public reports which are available on Bayer’s website at www.bayer.com. The Company undertakes no responsibility to update or conform to these forward-looking statements them to future events or developments.
